About one in three people will develop shingles in their lifetime and nearly all adults aged 50 years and older carry the inactive virus that causes it. But the the risk of develo ...
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
Additionally, Dr. Brangman says that the Tdap vaccine, which protects against tetanus, diphtheria and whooping cough, is also ...
Rhode Island has the highest vaccination rate across the country, while Mississippi was found to have the lowest, a new study ...
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback